Shattuck Labs (NASDAQ:STTK) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Shattuck Labs (NASDAQ:STTK) from a hold rating to a buy rating in a report issued on Saturday morning.

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Shattuck Labs in a research note on Thursday, January 22nd. Citigroup upped their target price on shares of Shattuck Labs from $4.00 to $7.00 and gave the company a “neutral” rating in a report on Friday, March 13th. Needham & Company LLC started coverage on shares of Shattuck Labs in a research report on Friday, March 6th. They issued a “buy” rating and a $25.00 price target on the stock. HC Wainwright upgraded shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 price target on the stock in a research report on Monday, December 1st. Finally, Wedbush boosted their price objective on shares of Shattuck Labs from $4.00 to $8.00 and gave the company an “outperform” rating in a research report on Friday, March 6th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.50.

Shattuck Labs Price Performance

Shares of STTK opened at $5.96 on Friday. The firm has a market capitalization of $426.50 million, a P/E ratio of -7.74 and a beta of 1.55. Shattuck Labs has a one year low of $0.69 and a one year high of $6.81. The business has a fifty day moving average of $4.76 and a 200 day moving average of $3.39.

Shattuck Labs (NASDAQ:STTK) last posted its earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.12). The firm had revenue of ($1.00) million during the quarter, compared to the consensus estimate of $0.17 million. Analysts expect that Shattuck Labs will post -1.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Shattuck Labs

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Turtle Creek Wealth Advisors LLC bought a new stake in Shattuck Labs during the 3rd quarter worth approximately $29,000. Virtu Financial LLC purchased a new position in Shattuck Labs during the third quarter valued at approximately $38,000. Squarepoint Ops LLC bought a new position in shares of Shattuck Labs in the third quarter worth approximately $46,000. Mallini Complete Financial Planning LLC bought a new position in shares of Shattuck Labs in the fourth quarter worth approximately $83,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Shattuck Labs in the fourth quarter worth $85,000. 58.74% of the stock is owned by hedge funds and other institutional investors.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.